UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 935

Sortiert nach

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Journal of clinical oncology, 2018-05, Vol.36 (14), p.1412-1418

2018

Volltextzugriff (PDF)

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

Cancer, 2020-07, Vol.126 (14), p.3219-3228

2020

Volltextzugriff (PDF)

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.1560-1568

2018

Volltextzugriff (PDF)

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

Clinical cancer research, 2019-10, Vol.25 (19), p.5832-5842

2019

Volltextzugriff (PDF)

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors

Cancer discovery, 2013-12, Vol.3 (12), p.1364-1377

2013

Volltextzugriff (PDF)

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (3), p.546-556

2019

Volltextzugriff (PDF)

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

Journal of thoracic oncology, 2015-03, Vol.10 (3), p.500-508

2015

Volltextzugriff (PDF)

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Molecular cancer therapeutics, 2018-05, Vol.17 (5), p.885-896

2018

Volltextzugriff (PDF)

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database

Journal of thoracic oncology, 2018-03, Vol.13 (3), p.436-446

2018

Volltextzugriff (PDF)

Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial

Nature communications, 2023-09, Vol.14 (1), p.5332-5332, Article 5332

2023

Volltextzugriff (PDF)

Outperforming the Conventional Scaling Rules in the Quantum-Capacitance Limit

IEEE electron device letters, 2008-04, Vol.29 (4), p.372-374

2008

Volltextzugriff (PDF)

Silicon nanowire tunneling field-effect transistors

Applied physics letters, 2008-05, Vol.92 (19), p.193504-193504-3

2008

Volltextzugriff (PDF)

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC

PloS one, 2018-11, Vol.13 (11), p.e0208097-e0208097

2018

Volltextzugriff (PDF)

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

Clinical lung cancer, 2014-01, Vol.15 (1), p.1-6

2014

Volltextzugriff (PDF)

Lateral Strain Profile as Key Technology Booster for All-Silicon Tunnel FETs

IEEE electron device letters, 2009-06, Vol.30 (6), p.656-658

2009

Volltextzugriff (PDF)

Tuning the emission characteristics of top-emitting organic light-emitting devices by means of a dielectric capping layer: An experimental and theoretical study

Journal of applied physics, 2003-10, Vol.94 (8), p.5290-5296

2003

Volltextzugriff (PDF)

Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape

Journal of thoracic oncology, 2024-01, Vol.19 (1), p.10-12

2024

Volltextzugriff (PDF)

Tuning Optoelectronic Properties of Ambipolar Organic Light- Emitting Transistors Using a Bulk-Heterojunction Approach

Advanced functional materials, 2006-01, Vol.16 (1), p.41-47

2006

Volltextzugriff (PDF)

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Journal of clinical oncology, 2021-07, Vol.39 (21), p.2339-2349

2021

Volltextzugriff (PDF)

Phosphorescent top-emitting organic light-emitting devices with improved light outcoupling

Applied physics letters, 2003-01, Vol.82 (3), p.466-468

2003

Volltextzugriff (PDF)

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Journal of clinical oncology, 2018-07, Vol.36 (19), p.1905-1912

2018

Volltextzugriff (PDF)

Progress and Challenges in Non-small Cell Lung Cancer and Colorectal Cancer With Pan-KRAS Inhibitors

Oncology (Williston Park, N.Y.), 2020-11, Vol.34 (11), p.508

Riess, Jonathan W

2020

Volltextzugriff (PDF)

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1248-1268

2018

Volltextzugriff (PDF)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

JTO clinical and research reports, 2023-03, Vol.4 (3), p.100459-100459, Article 100459

2023

Volltextzugriff (PDF)

1 – 25 von 935

Suche als RSS-Feed

Aktive Filter

PublikationsformBuchkapitel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(785)
Mit Volltextzugriff
(812)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database

Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial

Outperforming the Conventional Scaling Rules in the Quantum-Capacitance Limit

Silicon nanowire tunneling field-effect transistors

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

Lateral Strain Profile as Key Technology Booster for All-Silicon Tunnel FETs

Tuning the emission characteristics of top-emitting organic light-emitting devices by means of a dielectric capping layer: An experimental and theoretical study

Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape

Tuning Optoelectronic Properties of Ambipolar Organic Light- Emitting Transistors Using a Bulk-Heterojunction Approach

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Phosphorescent top-emitting organic light-emitting devices with improved light outcoupling

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Progress and Challenges in Non-small Cell Lung Cancer and Colorectal Cancer With Pan-KRAS Inhibitors

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

Aktive Filter

Suchergebnisse filtern